Why Infosys shares plunged 6% after Q4 nos, share buyback

Analysts believe the Rs 9,200 crore share buyback announced by the IT major should protect the downside for the stock.

Reuters
The Infosys stock fell 5.59% to hit a low of Rs 1,320.35 on BSE on Thursday.
NEW DELHI: Infosys' 6 per cent fall in Thursday's trade mirrored an overnight fall in Infosys' American depository receipts (ADRs), as analysts said deal wins moderated in March quarter, and like TCS, the numbers lacked positive surprises.

"The sequential growth was uninspiring and the FY22 guidance too was deemed conservative. Beating expectations every time isn't easy," said analysts, who believe the Rs 9,200 crore share buyback announced by the IT major should protect the downside for the stock.

The stock fell 5.59 per cent to hit a low of Rs 1,320.35 on BSE on Thursday. In overnight trade, Infosys ADRs fell 5.98 per cent to close at $17.31.


Credit Suisse called the March quarter earnings unimpressive and said FY22 guidance was conservative. While maintaining an 'outperform' rating on the stock, the brokerage said muted growth for the BFSI vertical led to weak sequential sales.

7 stocks analysts recommend for handsome near-term returns
1/8

Which stocks to buy now? Wild swings in the market at the onset of the earnings season and the reimposition of lockdowns to curb the Covid-19 pandemic have left many investors wondering whether there are any untapped opportunities to make money on Dalal Street.



Here are seven technical picks that analysts believe can help traders make good gains in the coming weeks:

Which stocks to buy now? Wild swings in the market at the onset of the earnings season and the reimposition of lockdowns to curb the Covid-19 pandemic have left many investors wondering whether there..
Read More

Cipla has gained momentum after breaking out from an all-time high, with momentum indicators MACD and RSI indicating further upside. A 'buy' is recommended on 'Cipla' above Rs 905 for a target of Rs 995, with a stop loss at Rs 790.



(Analyst: Ashis Biswas, Head of Technical Research, CapitalVia Global Research)

Cipla has gained momentum after breaking out from an all-time high, with momentum indicators MACD and RSI indicating further upside. A 'buy' is recommended on 'Cipla' above Rs 905 for a target of Rs ..
Read More

An upmove in the stock near the support of Rs 275 after the formation of a positive candlestick pattern hints at a crucial bottom reversal at the lows. A further rise is likely to confirm this pattern. Buying at the current price and adding on dips towards Rs 280 is recommended on the stock for a target of Rs 320 in the coming 3-4 weeks, with a stop loss at Rs 272.



(Analyst: Nagaraj Shetti, Technical Research Analyst, HDFC Securities)

An upmove in the stock near the support of Rs 275 after the formation of a positive candlestick pattern hints at a crucial bottom reversal at the lows. A further rise is likely to confirm this patter..
Read More

A correction in the stock appears to be ending in the stock around Rs 98-100 levels on the weekly chart, with the weekly 14-period Relative Strength Index looking positive. Buying can be initiated at the current levels, and dips towards Rs 98 can be used to add, for a target of Rs 113 in the next 3-4 weeks with a stop loss at Rs 95.



(Analyst: Nagaraj Shetti, Technical Research Analyst, HDFC Securities)

A correction in the stock appears to be ending in the stock around Rs 98-100 levels on the weekly chart, with the weekly 14-period Relative Strength Index looking positive. Buying can be initiated at..
Read More

The stock appears to be in a strong upmove, with a long green candle that closed at a day's high confirming the bullish outlook. Overall depression in the market has not dampened the rally in Oriental Aromatics with moving averages showing a good crossover effect as a bullish sign. The stock can be bought at the current levels from a 3-4 week view for a target of Rs 800 and then Rs 850, with a stop below Rs 640.



(Analyst: Manish Shah, Trader, Researcher and Trading Coach, Niftytriggers.com)

The stock appears to be in a strong upmove, with a long green candle that closed at a day's high confirming the bullish outlook. Overall depression in the market has not dampened the rally in Orienta..
Read More

The stock has support at its 55-day exponential moving average, indicating a positive outlook, with momentum indicators MACD and RSI also hinting at continuation of momentum. Investors may take a long position from a medium-term perspective for a target of Rs 2,450 with a stop loss at Rs 1,920.



(Analyst: Ashis Biswas, Head of Technical Research, CapitalVia Global Research)

The stock has support at its 55-day exponential moving average, indicating a positive outlook, with momentum indicators MACD and RSI also hinting at continuation of momentum. Investors may take a lon..
Read More

The stock has been trading above its 200-day moving average, hinting at continuation of a positive momentum. Investors can look at buying Graphite for a target of Rs 790 in the medium term with a stop loss at Rs 440.



(Analyst: Ashis Biswas, Head of Technical Research, CapitalVia Global Research)

The stock has been trading above its 200-day moving average, hinting at continuation of a positive momentum. Investors can look at buying Graphite for a target of Rs 790 in the medium term with a sto..
Read More

The stock appears to be moving in a range on the weekly chart with the possibility of a rectangle pattern. The magnitude of this range looks fairly wide, which indicates a good-risk reward ratio if the price rallies to Rs 1,200 over the next couple of weeks. Alembic Pharma has confirmed a breakout from a double bottom pattern and a rally is expected till Rs 1,100, and then Rs 1,180. A long position can be held for 3-4 weeks with a stop below Rs 890.



(Analyst: Manish Shah, Trader, Researcher and Trading Coach, Niftytriggers.com)

The stock appears to be moving in a range on the weekly chart with the possibility of a rectangle pattern. The magnitude of this range looks fairly wide, which indicates a good-risk reward ratio if t..
Read More
CLSA said the 2 per cent sequential constant currency (CC) revenue growth may be 'optically' disappointed. Acknowledging that beating expectations consistently is tough, the brokerage said beating rising expectations is even tougher. It said Infosys is its preferred IT play and suggesting a price target of Rs 1,660. Credit Suisse sees the stock at Rs 1,725.

Peer TCS reported a 4.2 per cent rise in sequential revenues on constant currency terms. Ebitda margin rose 20 basis points sequentially to 26.8 per cent compared with a 90 basis points fall for Infosys at 24.5 per cent. TCS' deal wins for the quarter stood at $9.2 billion, its highest ever. In contrast, Infosys deal wins stood at $2.1 billion. That said, March quarter is generally a seasonally weak period for Infosys.
ADVERTISEMENT

On the guidance front, Infosys projected 12-14 per cent CC growth in FY22 against double-digit revenue growth for TCS. Infosys sees FY22 Ebit guidance at 22-24 per cent against TCS' aspirational band of 26-28 per cent.

Valuation wise, Infosys stock trades at 26 times FY22 expected earnings per share (EPS) against TCS' 29 times. UBS said since Infosys' Q4 earnings were below expectations and, like TCS, there was a lack of positive surprise, the earnings cycle seemed to have peaked for now. It sees a likely cut in consensus earnings, which may trigger a negative reaction.

"Buyback should offer downside support for Infosys," it said.

Phillip Capital said Infosys looks set to report mid-teen growth in FY22, after a strong performance in covid impacted FY21. "While the stock might remain a bit weak in the near term due to expectations coming down and relatively expensive valuations. We remain positive for the medium to long term on the strong growth story, driven by a robust demand environment," it said.
ADVERTISEMENT

This brokerage said the overhang of the second Covid Wave and possible lockdowns in India would keep the IT sector in flavour in the near term, despite valuations bordering on expensive.
ADVERTISEMENT
READ MORE

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Markets › Stocks › News › Why Infosys shares plunged 6% after Q4 nos, share buyback
Text Size:AAA
Success
This article has been saved

*

+